Director, Global Commercial Strategy, Iza-bren

Working with Us Challenging. Meaningful. Life-changing. Those aren’t words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department. From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it.

You’ll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high-achieving teams. Take your career farther than you thought possible. Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.

Read more:

Position Summary:

The Director, Global Commercial Strategy, Iza-bren will be an integral member of the Global Commercial Strategy (GCS) team and reports to the VP, Global Commercial Strategy Lead. This individual will lead global commercial strategy of key indications for iza-bren (EGFRxHER3 bispecific ADC). This role requires close, day-to-day partnership with Clinical Development, Biostatistics, Regulatory, Forecasting/Competitive Intelligence, Market Access, and Medical. The candidate must be comfortable operating in a fast-paced, ambiguous environment with high expectations on quality and speed of deliverables, translating clinical and scientific uncertainty into clear commercial perspective and executive-ready strategic direction.

• Own commercial asset strategy for assigned iza-bren indication(s) — ensuring alignment with the GPT team and broader oncology portfolio strategy
• Lead development and iterative refinement of Target Product Profiles (TPPs), including designing and pressure-testing market research, gaining TL feedback, and thoughtful utilization of analogs to validate share/utilization assumptions
• Lead and continuously refine commercial forecasting, market sizing, and revenue/valuation models; translate clinical, regulatory, or biomarker-inclusion changes into quantified commercial recommendations for cross-functional decision-making, and make clear recommendations under uncertainty
• Shape and evolve the Clinical Development Plan (CDP) in partnership with Clinical Development, informing indication and study prioritization based on commercial assessment, competitive dynamics, and portfolio trade-offs
• Develop executive-level governance narratives and materials that translate complex clinical and commercial data into clear, decision-ready recommendations for senior leadership and governance forums
• Monitor and synthesize the relevant competitive landscape, proactively flagging implications for iza-bren strategy and commercial opportunity
• Build and maintain excellent stakeholder networks across the GPT, global commercial strategy team, key regional partners and across matrix functions, to advance business objectives and ensure smooth progress as the program moves through key inflection points
• Represent commercial strategy in the BMS/Syst Immune alliance and governance forums, ensuring commercial input is reflected in joint decision-making on trial design, label strategy, and lifecycle planning

• The ideal Director, Global Commercial Strategy candidate brings asset strategy experience in oncology, deep commercial assessment capability, and proven ability to influence cross-functionally and at governance forums.
• They should demonstrate comfort translating clinical uncertainty into clear strategic direction, and shaping portfolio decisions through rigorous, executive-ready analysis.
• BS/BA or equivalent required; an MBA or other advanced degree preferred.
• Minimum 6-8 years of pharmaceutical/biotech commercial strategy, marketing, or top-tier consulting experience; oncology experience strongly preferred.
• Experience shaping Clinical Development Plan (CDP) evolution and/or indication prioritization in partnership with Clinical Development.
• Demonstrated end-to-end asset strategy experience in…